ORIFARM PI A/S: Financial statements 2023
CVR: 27347177
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
ORIFARM PI A/S (CVR 27347177) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -95,000 and a net result of DKK 253,407,000 compared with DKK 182,945,000 the year before. Equity in the 2023 report amounted to DKK 940,668,000. The solvency ratio was 87.8%.
- Gross Profit
- DKK -95,000
- Profit/Loss
- DKK 253,407,000
- Equity
- DKK 940,668,000
- Total Assets
- DKK 1,070,912,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -95K | 253.4M | 940.7M | - |
| 2022 | - | -73K | 182.9M | 687.4M | 0 |
| 2021 | - | -76K | 206M | 760M | 0 |
| 2020 | - | -57K | 208.7M | 563.8M | 0 |
| 2019 | - | -71K | 191.8M | 554.4M | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
ORIFARM PI A/S has published its annual report for 2022. Gross profit came to DKK -73,000, and the net result was DKK 182,945,000.
About ORIFARM PI A/S
ORIFARM PI A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2003. The company is registered under the industry Finansielle holdingselskaber. The company was previously named ORIFARM HOLDING A/S. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GROUP A/S. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK -446,000 and a net result of DKK 298,665,000 compared with DKK 320,939,000 the year before. Equity in the 2025 report amounted to DKK 1,391,995,000.